- 掃描二維碼關(guān)注儀器無憂網(wǎng)微信公眾平臺
- 您可以獲得:
- 1.更高效的咨詢方式
- 2.更便利的瀏覽體驗
- 3.實時的動態(tài)信息獲取
- 儀器無憂網(wǎng)
- 服務(wù)中心
Viral Antigens
美國Viral Antigens www.meridianlifescience.com
About Viral Antigens Brand - "World-leading Supplier of Viral Proteins"
Viral Antigens, Inc. (VAI) was founded in September of 1982 to commercialize techniques for producing high quality antigens and viral components and attaching them to latex beads. Research on rubella virus at the University of Tennessee at Memphis led to the development of a novel test to detect rubella virus specific antibodies. The test was licensed to Becton Dickinson (BD) to market the product with VAI manufacturing the rubella coated latex beads. BD's Rubascan Test Kit was highly successful capturing 50% market share within the first three years. VAI went on to develop CMV and VZV coated latex beads to expand BD's product line.
Due to our reputation of high product quality, VAI grew to be a recognized leader in supplying standard and custom antigens to the majority of the leading diagnostic companies in the U.S.A. and around the world.
In 1986 VAI expanded its menu to the veterinary market by developing a latex test to detect antibodies against pseudorabies virus (PRV) in pigs. The company elected to manufacture and market the PRV Antibody Test Kit to a regulated market consisting of state and state-approved veterinary laboratories. In 1992, we continued our growth into the veterinary market with the introduction of our Equine Infectious Anemia Test Kit. As a response to the vet market needs, in 1994 VAI introduced an automated version of the PRV test, Autolex®.
Meridian Bioscience, Inc. purchased VAI in September of 2000. VAI continued to operate as a wholly-owned subsidiary of Meridian Bioscience, Inc. until March of 2007 when it became integrated as a brand into Meridian Life Science, Inc. The Viral Antigens brand now produces over 80 products for the human and veterinary biotechnology industry. Viral Antigens continues to supply current customers while expanding its product portfolio of new and novel antigens along with providing custom contract antigen and assay development services.